Oxymetazoline
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Oxymetazoline
- Pharmacist Assessment Report
- Oxymetazoline: From Pharyngitis and Common Cold to Nasal Cavity Disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Oxymetazoline: From Pharyngitis and Common Cold to Nasal Cavity Disease
One-Sentence Summary
Oxymetazoline is a topical alpha-adrenergic agonist nasal decongestant, originally used for pharyngitis and the common cold. The TxGNN model predicts it may be effective for nasal cavity disease, but the data compiled for this report include no registered clinical trials and only 5 publications, mostly indirect or low-tier (clinical studies, case reports and one animal study).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pharyngitis; common cold (the ARTG entry has no indication text recorded) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 0.9996 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, oxymetazoline is a topical alpha-1/alpha-2 adrenergic agonist. It constricts the blood vessels of the nasal mucosa, which reduces congestion and improves nasal patency. This is an inference from established pharmacology, not from the provided record. Pharmacology data also show binding to several serotonin receptors (5-HT1B, 5-HT1D, 5-HT2C) and all alpha-adrenoceptor subtypes.
The original indications (common cold, pharyngitis) are upper airway conditions in which nasal mucosal swelling is a key symptom. “Nasal cavity disease” is a broad category, so decongestion could plausibly extend to related conditions such as rhinitis or sinusitis. Because the category is so broad, however, the prediction is not specific enough to guide a defined clinical use. Much of it overlaps with the drug’s current labelled use rather than being truly new.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9929658 | 1998 | Clinical study | Ann N Y Acad Sci | Effects of the common cold (acute rhinitis) on olfactory function in 36 subjects, using chemosensory evoked potentials and acoustic rhinometry of nasal volume |
| 8615587 | 1996 | Animal study | Ann Otol Rhinol Laryngol | Oxymetazoline nose drops vs placebo in experimental bacterial sinusitis in 14 rabbits, assessing effects on local tissue defence |
| 25496205 | 2015 | Clinical study | J Plast Surg Hand Surg | Nasal patency measured by acoustic rhinometry in children after cleft lip and palate repair; indirect relevance |
| 28490409 | 2017 | Case series / technique report | Am J Rhinol Allergy | Endoscopic coblation for nasal telangiectasias in hereditary haemorrhagic telangiectasia; indirect relevance |
| 38024464 | 2023 | Case report | Glob Pediatr Health | Rhinoscleroma in a 9-year-old boy; indirect relevance |
None of these publications is a randomised trial demonstrating oxymetazoline efficacy in a defined nasal cavity disease.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11711J | Pharmacy Action Nasal Decongestant | Nasal spray 500 micrograms per mL (0.05%), 20 mL | Not recorded in the data compiled for this report |
Safety Considerations
Labelled warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
- Contraindication associations (knowledge graph, not label text): The knowledge graph links oxymetazoline with caution in hypertension, heart disease and coronary artery disease, cardiovascular disease, arteriosclerosis and atherosclerosis, diabetes mellitus and diabetic ketoacidosis, benign prostatic hyperplasia, angle-closure glaucoma, hyperthyroidism (including Graves disease and thyrotoxicosis), eye infections and conjunctivitis, and vision disorders. These reflect its sympathomimetic activity and should be verified against the PI.
- Pharmacology/target interactions: Activity at 5-HT1B, 5-HT1D, 5-HT2C and alpha-1A/1B/1D and alpha-2A/2B/2C adrenoceptors. No drug-drug interaction data with specific medicines were provided. Concurrent use with monoamine oxidase inhibitors is a recognised concern for sympathomimetics and should be checked against the PI.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there are no registered trials. The supporting literature is indirect or low-tier, and “nasal cavity disease” is too broad to define a new indication. It largely restates the drug’s existing decongestant use. A key data gap (the ARTG indication text and the safety information) also remains.
To proceed, the following is needed:
- A specific target condition (e.g. allergic or infective rhinitis, sinusitis) instead of the broad “nasal cavity disease”
- Controlled clinical evidence for that condition
- Mechanism of action data confirmed from DrugBank
- The TGA PI for the ARTG entry, covering approved indication, warnings and contraindications
- A safety plan addressing cardiovascular and other sympathomimetic risks, including limits on duration of use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.